We spotted something big in the options flow today. |
A single buyer stepped in and purchased 10,484 SOFI April 10, 2026 $18 Calls at $0.54 each. That's over $56,000 in premium on a trade that expires in less than three weeks. This isn't a hedge. This isn't a covered call adjustment. This is someone making a directional bet that SOFI is going higher — fast. |
And when we see this kind of size, with this kind of urgency, we pay attention. |
|
Big Pharma's $5000B White Flag Is One Startup's Ticket (Ad) |
|
Big Pharma spent decades and billions trying to solve osteoarthritis, a $5000B market they've never cracked. |
Thankfully, Cytonics figured out why they keep failing: joints are attacked by multiple culprits at once, and Big Pharma only ever went after one at a time. |
So they discovered a way to get them all, potentially creating the first therapy to actually address the root cause of osteoarthritis at the molecular level. It's proven across 10,000+ patients. Now, they're pushing toward FDA approval on a 200% more potent version that can be manufactured at scale. |
The first human safety trial is already complete with zero adverse events. If approved, the more than 500M osteoarthritis patients worldwide could have their long-needed solution. |
Big Pharma created this opening. Maximize your piece of Cytonics today by claiming time-sensitve bonuses before the March 26 deadline. |
|
The Trade Breakdown |
Let's keep this simple. Here's exactly what happened: |
Ticker: SOFI (SoFi Technologies) Contract: April 10, 2026 $18 Calls Price Paid: $0.54 per contract Volume: 10,484 contracts Total Premium: approx. $56,613 Expiration: 17 days from now
|
This buyer needs SOFI above $18.54 by April 10th to break even. Anything above that is pure profit. And with SOFI already showing momentum, the math gets interesting quickly. |
|
Why This Trade Matters |
When someone puts $56K into short-dated calls on a single name, it tells you three things. |
First, they have conviction. This isn't a lotto ticket sprinkled across ten different names. This is concentrated capital in one direction on one stock with a tight expiration window. That kind of sizing usually comes from someone who has done their homework — or has access to information flow that most retail traders don't see. |
Second, the timing is aggressive. April 10th is 17 days away. That means this buyer isn't waiting around for a quarterly earnings beat or a macro catalyst six months from now. They believe something is happening with SOFI in the next two to three weeks that will push the stock through $18 and beyond. Whether that's: |
A product announcement or partnership Analyst upgrades or price target revisions Broader fintech sector rotation Technical breakout above a key resistance level
|
Whatever the catalyst, they're not buying time — they're buying urgency. |
Third, the risk-reward is asymmetric. At $0.54 per contract, the downside is defined. You can't lose more than what you paid. But if SOFI rips to $19 or $20 in the next two weeks, these calls could double or triple. That's the kind of setup institutional flow traders look for — limited downside, explosive upside, and a short fuse to keep you honest. |
|
Our Last Two Hedge Fund Flow Trades Are Both Up 50% |
This is why we follow the smart money. |
The last two Hedge Fund Trades of the Day we flagged for our members are both sitting at +50% gains right now. Not over months. Not over quarters. In days. That's what happens when you identify the right flow, at the right time, with the right structure. |
We don't chase every unusual options print that hits the tape. Most of them are noise — hedges, rolls, spread legs, and institutional portfolio adjustments that look exciting but mean nothing directionally. The skill is filtering signal from noise. And right now, our filter is hot. |
The pattern is clear. When we see concentrated size in short-dated calls, from buyers who are paying up at the ask, on names with technical momentum and fundamental tailwinds — those trades have been printing. Two in a row at +50% confirms the framework is working. |
|
Today's New Trade of the Day |
Based on today's flow and the setup we just broke down, we're calling this the Trade of the Day: |
|
Notice we're giving ourselves an extra week compared to the whale's trade. The institutional buyer went with April 10th expiration. We're buying April 19th. That gives us nine additional days of runway for the thesis to play out, which reduces the time decay risk while still keeping the premium cheap enough to offer strong upside. |
At $0.54 entry and a $0.75 target, this is a clean swing trade. You don't need SOFI to do anything dramatic. A steady grind above $18 over the next two to three weeks gets you there. And if the institutional flow is right and the stock accelerates, the upside could be significantly more than our conservative target. |
|
Final Takeaway |
Wall Street doesn't announce its moves. It doesn't send press releases before it buys. It speaks through the tape — and today the tape is screaming SOFI. |
Someone with deep pockets and a short time horizon just committed $56,000 to a bet that SOFI is heading higher. Our last two Hedge Fund Trades of the Day are both up 50%. And now we're stepping into the same flow with a defined risk, defined target, and a structure that gives us room to be right. |
This is how you trade alongside the smart money — not by guessing what they'll do, but by watching what they've already done. |
Trade smart. Manage your risk. And let the flow do the talking. |
|
|
*Disclaimer: This is a paid advertisement for Cytonics Regulation CF offering. Please read the offering circular at https://cytonics.com/ |
Equity crowdfunding investments in private placements, and start-up investments in particular, are speculative and involve a high degree of risk. Investors who cannot afford to lose their entire investment should not invest. Companies seeking startup investment through equity crowdfunding tend to be in earlier stages of development, and their business model, products, and services may not yet be fully developed, operational, or tested in the public marketplace. |
There is no guarantee that the stated valuation and other terms are accurate or in agreement with the market or industry valuations. Further, investors may receive illiquid and/or restricted stock that may be subject to holding period requirements and/or liquidity concerns. |
DealMaker Securities LLC, a registered broker-dealer, and member of FINRA | SIPC, located at 30 East 23rd Street, 2nd Floor, NY, NY 10010, is the Intermediary for this offering and is not an affiliate of or connected with the Issuer. Please check our background on FINRA's BrokerCheck. DealMaker Securities LLC does not make investment recommendations. DealMaker Securities LLC is NOT placing or selling these securities on behalf of the Issuer. DealMaker Securities LLC is NOT soliciting this investment or making any recommendations by collecting, reviewing, and processing an investor's documentation for this investment. DealMaker Securities LLC conducts Anti-Money Laundering, Identity and Bad Actor Disqualification reviews of the Issuer, and confirms they are a registered business in good standing. DealMaker Securities LLC is NOT vetting or approving the information provided by the Issuer or the Issuer itself. Contact information is provided for Investors to make inquiries and requests to DealMaker Securities LLC regarding Regulation CF in general, or the status of such investor's submitted documentation, specifically. DealMaker Securities LLC may direct Investors to specific sections of the Offering Circular to locate information or answers to their inquiry but does not opine or provide guidance on issuer related matters. |
This content may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. These forward-looking statements are based on the beliefs of, assumptions made by, and information currently available to the company's management. When used in the offering materials, the words "estimate," "project," "believe," "anticipate," "intend," "expect" and similar expressions are intended to identify forward-looking statements. These statements reflect management's current views with respect to future events and are subject to risks and uncertainties that could cause the company's actual results to differ materially from those contained in the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. The company does not undertake any obligation to revise or update these forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events. |
Past performance is not a guarantee of future results. Current performance may be lower or higher than the performance quoted. |
Disclaimer: This content is for educational purposes only and does not constitute financial advice. Options trading involves risk, and not all trades will be profitable. Always manage risk responsibly. |
Tidak ada komentar:
Posting Komentar